Chi-Med’s surufatinib an Orphan drug in U.S. for pancreatic neuroendcrine tumors

The FDA has granted Orphan Drug designation to Hutchison China MediTech’s (NASDAQ:HCM) surufatinib for the treatment of pancreatic neuroendocrine tumors (“NET”).

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Surufatinib is under investigation in multiple solid tumors in China and the U.S., both as a monotherapy and in combination with immunotherapies.

https://seekingalpha.com/news/3521700-chi-meds-surufatinib-orphan-drug-u-s-pancreatic-net